SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.
Research SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. (603858.SS) on Bullrun: market cap CNY 15.65B, P/E 53.0, dividend yield 1.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker603858.SS
- ExchangeSS
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCNY
- Market capCNY 15.65B
- P/E53.0
- Dividend yield1.2%
- Financial periodQ2 2026
- RevenueCNY 2.42B
- Net incomeCNY 182.17M
- Free cash flowCNY 262.66M
- Gross margin58.9%
Valuation Snapshot
latest market cap is CNY 15.65B; P/E is 53.0; dividend yield is 1.2%.
Peer valuation comparison
Latest P/E is 53x versus a Healthcare sector median of 21.8x (143.2% above).
Latest dividend yield is 1.21% versus a Healthcare sector median of 2.4% (49.6% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | CNY 15.65B | 53.0 | 4.4% | 0.66 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.66 CNY, yield 1.2%.
About SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicines in China and internationally. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China.
ETFs that hold SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.
US-listed ETFs
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is held by 12 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | <0.01% | 0.04% |
| Schwab Emerging Markets Equity ETF (SCHE) | <0.01% | 0.06% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.'s market cap?
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.'s market capitalization is CNY 15.65B.
What is SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.'s P/E ratio?
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.'s price-to-earnings (P/E) ratio is 53.0.
Does SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. pay a dividend?
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. has a dividend yield of 1.2%.
What does SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. do?
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicines in China and internationally. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China.